Andrew Joseph Kocab

Onl Therapeutics, Inc.

$699,528

Attributed

$1,399,056

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $618.2K · FY2018–22

$1M$750K$500K$250K$0

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$1,399,056 · 1

By mechanism

R42$1,399,056 · 1

Top collaborators

James T Handa5 shared

Most similar at Onl Therapeutics, Inc.

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Exhibits”

John E West · University Of Texas At Austin$94,000,000
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$44,740,553
Evan Z Macosko · Broad Institute, Inc.$27,107,011
Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$11,832,144
Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
Ashok Kumar Krishnamurthy · Univ Of North Carolina Chapel Hill$10,798,287

Research focus

ExhibitsGene TherapyDoseEffective TherapyExposure To Cigarette SmokeExudative Age-Related Macular DegenerationAtrophicAcuteAgingEffectivenessAdvanced DiseaseBlindnessCause Of DeathAntioxidantsCell DeathCellsAutophagocytosisAge Related Macular DegenerationChronicBaby BoomerBiological Adaptation To StressEconomic ImpactBiotechnologyGlaucoma

Grant awards (5)

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$120,000

R42 · FY2022 · EY · contact PI

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$352,130

R42 · FY2021 · EY · contact PI

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$8,541

R42 · FY2021 · EY · contact PI

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$618,183

R42 · FY2020 · EY · contact PI

Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$300,202

R42 · FY2018 · EY · contact PI